Focus Partners Wealth
ELDN icon

Focus Partners Wealth’s Eledon Pharmaceuticals ELDN Stock Holding History

Focus Partners Wealth’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-317,443
Closed -$479K – 2709
2025
Q4 		$479K Buy
+317,443
New +$755K ﹤0.01% 1970

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Focus Partners Wealth's ELDN Position: Q1 2026 in Review

Focus Partners Wealth sold out of Eledon Pharmaceuticals (ELDN) in Q1 2026, closing a stake of 317,443 shares — an estimated $479K sold.

Focus Partners Wealth first reported a position in ELDN in Q4 2025 and held it in 1 quarter. The position peaked at $479K in Q4 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Focus Partners Wealth reported no remaining Eledon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 317,443 Eledon Pharmaceuticals shares in Q1 2026, an estimated $479K.
  • Focus Partners Wealth first reported a position in Eledon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Focus Partners Wealth's Eledon Pharmaceuticals position peaked at $479K in Q4 2025.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.